In the interim report that Acarix submitted today, 12 November 2020, there is a minor error under the
heading “Capitalization” (page 4 in the interim report) where the last sentence is to end with 2022 and
The correct sentence reads: " The Board assesses that cash balance as of the balance sheet date will
cover the Company’s working capital requirements until the second quarter of 2022."
A corrected version of the interim report is available at www.acarix.se
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, email@example.com) is Certified Advisor of Acarix.